Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-MOmentum
NCT02200770Phase 3Completed
- Sponsor
- MedImmune
- Start
- Apr 2015
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by MedImmune. Started Apr 2015; status: completed.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT02200770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200770.